Guruprasad Pattar is an Ophthalmology physician affiliated with The Eye Care Institute. OpenAlex indexes 18 publications with 632 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1536 Story Ave
Louisville, KY 402061738
Telephone
502-589-1500Provider last certified this registry record 7 Sept 2023.
Clinical trials
- Long-term Effects of Acoltremon vs. Control in Dry Eye Disease
Sponsor: The Eye Care Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year202511 payments
- Tarsus Pharmaceuticals, Inc.Program year20255 payments
- Bausch & Lomb Americas Inc.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
84.2%Antineovascularisation agents69.2%Faricimab-svoa100%Part B, office-administered≥17 patientsCorticosteroid5.4%Prednisolone Acetate79%Fluorometholone21%Part D≥147 patients+ 5 more classes in this area
Cancer & immunology
7.5%Calcineurin inhibitor4.1%Restasis52%Cequa35%Cyclosporine13%Part D≥46 patientsVascular Endothelial Growth Factor Inhibitor3.3%Aflibercept100%Part B, office-administered≥33 patientsMusculoskeletal
5.3%Cyclooxygenase Inhibitor5.3%Ketorolac Tromethamine100%Part D≥158 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”